

Edgar Filing: HAEMONETICS CORP - Form 8-K

HAEMONETICS CORP  
Form 8-K  
July 30, 2004

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 30, 2004

HAEMONETICS CORPORATION

-----  
(Exact name of registrant as specified in its charter)

Massachusetts	1-10730	04-2882273
----- (State or other jurisdiction of incorporation)	----- (Commission File Number)	----- (IRS Employer Identification No.)

400 Wood Road Braintree, MA	02184
----- (Address of principal executive offices)	----- (Zip Code)

Registrant's telephone number, including area code (781) 848-7100

-----  
(Former name or former address if changed since last report)  
=====

Item. 5 OTHER EVENTS AND REGULATION FD DISCLOSURE

On July 30, 2004, Haemonetics Corporation, (the "Company") announced the reelection of Dr. Yutaka Sakurada to the Company's Board of Directors. Dr. Harvey Klein withdrew his name from the slate of candidates to be elected to the Board in response to a recently announced policy by National Institutes of Health ("NIH") against having NIH employees serve on for-profit boards. Dr. Klein serves as the Chief of the Department of Transfusion medicine at the Warren G. Magnuson Clinical Center of NIH.

Item. 7 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1: Press Release of Haemonetics Corporation dated July 30, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

(Registrant)

Edgar Filing: HAEMONETICS CORP - Form 8-K

Date: July 30, 2004

By: /s/ Ronald J. Ryan

-----  
Ronald J. Ryan, Vice President and  
Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.	Subject Matter
99.1	Press Release of Haemonetics Corporation dated July 30, 2004.

3